NCT07523360 A Digital Cognitive Intervention for Intrusive Memories After Trauma
| NCT ID | NCT07523360 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhu Zijian |
| Condition | Post-Traumatic Stress Disorder (PTSD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 123 participants |
| Start Date | 2026-06-10 |
| Primary Completion | 2028-04-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 123 participants in total. It began in 2026-06-10 with a primary completion date of 2028-04-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Intrusive traumatic memories frequently trigger severe distress and psychological disorders such as post-traumatic stress disorder (PTSD). Traditional therapies require explicit trauma recall, which often causes severe patient distress and may lead to treatment avoidance. To address this, our study introduces a less aversive intervention that combines unconscious visual processing with bilateral eye movements to reduce intrusive traumatic memories. Utilizing a randomized, three-arm design, we will compare standardized trauma-related images, patient-provided images, and neutral images, all paired with bilateral eye movements. We plan to recruit participants who have experienced severe trauma and report at least 5 intrusive memories per week, with a target final sample of 40 participants per arm. The primary outcome is the frequency of intrusive memories. Secondary and additional outcomes include PTSD severity, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), the PTSD Checklist for DSM-5 (PCL-5), and the Impact of Event Scale (IES), as well as depression, anxiety, borderline symptoms, functional improvement, subjective intervention distress, and dropout rates.
Eligibility Criteria
Inclusion Criteria: 1. Meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Criterion A for post-traumatic stress disorder (PTSD), which requires exposure to an event involving serious injury or a threat to one's own or another person's physical well-being, either through direct experience or witnessing. 2. Exhibit symptoms from at least three of the five core PTSD symptom domains outlined in DSM-5: intrusive memories (Criterion B), persistent avoidance of trauma-related stimuli (Criterion C), negative alterations in cognitions and mood (Criterion D), alterations in arousal and reactivity (Criterion E), and symptoms lasting for at least one month (Criterion F). 3. Have a total score of 33 or higher on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). 4. Have internet access and access to a personal computer. 5. Have not taken part in a previous study of this intervention conducted by this research team. Exclusion Criteria: 1. Fewer than 5 intrusive memories during the baseline week (Week 0). 2. An intelligence quotient (IQ) score lower than 80. 3. A current diagnosis of schizophrenia, obsessive-compulsive disorder (OCD), a severe personality disorder judged to interfere with treatment adherence, or acute suicidal behavior. 4. Severe substance dependence.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07523360 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Post-Traumatic Stress Disorder (PTSD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07523360 currently recruiting?
Yes, NCT07523360 is actively recruiting participants. Contact the research team at zhuzijian0203@snnu.edu.cn for enrollment information.
Where is the NCT07523360 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT07523360 clinical trial?
NCT07523360 is sponsored by Zhu Zijian. The trial plans to enroll 123 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.